Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Wall Street analysts are projecting that ResMed (RMD) will report Q4 earnings of $2.90 per share, up 13.7% year over year. Revenue is expected to reach $1.46 billion, an 8.4% increase from the same quarter last year. In the past 30 days, the consensus EPS estimate has been revised slightly downward by 0.1%, suggesting analysts have modestly adjusted expectations. Beyond headline figures, the article lists estimated key metrics commonly tracked by investors, including global revenue for Total Sleep and Breathing Health at $1.28 billion (+8.8%); Residential Care Software at $176.78 million (+5.9%); and Total Devices at $745.56 million (+7.5%).